Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Comunicato relativo all’approvazione del CdA sulla proposta di autorizzazione all’acquisto e alla disposizione di azioni proprie (Price Sensitive)

20.10.2021 Comunicato stampa_Il Consiglio di Amministrazione approva la proposta di autorizzazione all’acquisto e alla disposizione di azioni proprie

Philogen to Participate at the 2021 Virtual Stifel Healthcare Conference on November 15-17, 2021

Stifel Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri through a series of one-on-one meetings....

Philogen announces Philochem Patent Upheld

Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was...

Philogen announces R&D program update for Dekavil

Philogen S.p.A. announces an update on the worldwide license agreement with Pfizer to develop Dekavil, a novel investigational therapy for the treatment of autoimmune...

Philogen to attend the Antibody Engineering & Therapeutics on December 12-16 , 2021

Dario Neri, co-founder, CEO and CSO, is giving a presentation focused on Tripokin, a novel fusion protein capable of an exceptionally selective uptake at the tumor...

Philogen to attend the Cytokine-Based Cancer Immunotherapies Summit on November 30-December 2 , 2021

Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based...

Philogen to attend the Connective Tissue Oncology Society (CTOS) Virtual 2021 Annual Meeting on November 10-13, 2021

Philogen is presenting a ePoster on the results of the run-in part of the Phase II study with Fibromun plus Dacarbazine for patients with in third or later line...

Philogen to participate at the BIO-Europe Digital 2021 on October 25-28, 2021

Philogen participates at the BIO-Europe Digital 2021 BIO-Europe (informaconnect.com) - 2021, the international partnering event in the life science and pharma industry,...

Philogen Provides Corporate Update

Philogen provides corporate update

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2021 (Price sensitive) – Courtesy English Translation

20210928 Philogen Comunicato stampa_semestrale 2021- ENG

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions